Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Abeona Therapeutics Inc (ABEO) Insider Trading Activity

    Healthcare • Biotechnology • 84 employees

    Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

    Total Value

    -$280,330.97

    Total Shares

    831,147

    Average Trade Value

    -$11,213.24

    Most Active Insider

    Alvino Mark

    Total Activity: $136,764

    Largest Single Transaction

    $116,764

    by Alvino Mark on Jun 18, 2024

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Chief Executive Officer
    Director, Officer
    Oct 16, 2024 251 $1,642 903,887 (-0.0%) Payment of Exercise Price
    Chief Executive Officer
    Director, Officer
    Sep 28, 2024 18,798 $110,720 904,138 (-2.1%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Sep 28, 2024 6,388 $37,625 365,217 (-1.7%) Payment of Exercise Price
    Svp, General Counsel
    Officer
    Sep 28, 2024 6,579 $38,750 273,289 (-2.4%) Payment of Exercise Price
    Svp, General Counsel
    Officer
    Sep 20, 2024 496 $2,986 279,868 (-0.2%) Payment of Exercise Price
    Director
    Aug 26, 2024 11,797 $10,000 114,511 (+10.3%) Grant
    Director
    Aug 26, 2024 11,797 $0 144,365 (+8.2%) Grant
    Director
    Aug 26, 2024 11,797 $10,000 72,334 (+16.3%) Grant
    Director
    Aug 26, 2024 11,797 $10,000 113,731 (+10.4%) Grant
    Director
    Aug 26, 2024 11,797 $0 97,471 (+12.1%) Grant
    Director
    Aug 26, 2024 11,797 $10,000 118,265 (+10.0%) Grant
    Director
    Aug 13, 2024 11,044 $10,000 11,044 (+100.0%) Grant
    Director
    Aug 13, 2024 11,044 $10,000 11,044 (+100.0%) Grant
    Chief Financial Officer
    Officer
    Jul 21, 2024 1,055 $5,391 371,605 (-0.3%) Payment of Exercise Price
    Svp, General Counsel
    Officer
    Jul 8, 2024 102,689 $10,000 280,364 (+36.6%) Grant
    Director
    Jul 8, 2024 23,611 $10,000 106,468 (+22.2%) Grant
    Chief Financial Officer
    Officer
    Jul 8, 2024 155,200 $10,000 372,660 (+41.6%) Grant
    Director
    Jul 8, 2024 23,611 $10,000 60,537 (+39.0%) Grant
    Director
    Jul 8, 2024 23,611 $10,000 102,714 (+23.0%) Grant
    Chief Executive Officer
    Director, Officer
    Jul 8, 2024 424,000 $10,000 922,936 (+45.9%) Grant
    Director
    Jul 8, 2024 23,611 $10,000 132,568 (+17.8%) Grant
    Director
    Jul 8, 2024 23,611 $10,000 85,674 (+27.6%) Grant
    Director
    Jul 8, 2024 23,611 $10,000 101,934 (+23.2%) Grant
    Director
    Jun 18, 2024 25,821 $116,453 62,063 (-41.6%) Sale
    Director
    Jun 18, 2024 25,890 $116,764 36,926 (-70.1%) Sale